Zoetis Inc. (NYSE:ZTS) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Tuesday, June 10, in Rancho Palos Verdes, Calif. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 4:20 p.m. EDT (1:20 p.m. PDT). Zoetis Inc. (NYSE:ZTS) net profit margin is 11.40% and weekly performance is 3.39%. On last trading day company shares ended up $31.74. Analysts mean target price for the company is $35.55. Zoetis Inc. (NYSE:ZTS) distance from 50-day simple moving average (SMA50) is 5.93%.
Mylan Inc. (NASDAQ:MYL) made an official announcement on 4 June about its license agreement to sell the generic version of the painkiller capsules Celecoxib, also referred popularly as Celebrex, with Pfizer Inc. (NYSE:PFE). Mylan Inc. (NASDAQ:MYL) shares fell -0.22% in last trading session and ended the day on $49.73. MYL gross Margin is 44.80% and its return on assets is 4.50%.Mylan Inc. (NASDAQ:MYL) quarterly performance is -9.35%.
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) on 6 June said its experimental treatment for pancreatic cancer, called necuparanib, has been granted orphan-drug status by the Food and Drug Administration. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares moved up 3.14% in last trading session and was closed at $13.45, while trading in range of $13.00 – $13.51. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) year to date (YTD) performance is -23.93%.
The 2014 Annual Meeting of Stockholders of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was held on May 22, 2014. As of the close of business on April 1, 2014, the record date for the Annual Meeting, there were 75,858,681 shares of common stock entitled to vote, of which there were 67,569,356 shares present at the Annual Meeting in person or by proxy. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) ended the last trading day at $14.93. Company weekly volatility is calculated as 4.06% and price to cash ratio as 5.15.Neurocrine Biosciences, Inc. (NASDAQ:NBIX) showed a positive weekly performance of 7.49%.
Sagent Pharmaceuticals Inc. (NASDAQ:SGNT) Director Robert J. Flanagan sold 16,000 shares of the company’s stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $22.17, for a total transaction of $354,720.00. Following the transaction, the director now directly owns 6,996 shares in the company, valued at approximately $155,101. Sagent Pharmaceuticals Inc. (NASDAQ:SGNT) net profit margin is 9.70% and weekly performance is 2.10%. On last trading day company shares ended up $22.88. Analysts mean target price for the company is $23.71. Sagent Pharmaceuticals Inc. (NASDAQ:SGNT) distance from 50-day simple moving average (SMA50) is 5.59%.